What is ALS Phase 2-3 Study Arimoclomol?
CATEGORY:
NCT00706147 is a phase II/III randomized, placebo-controlled trial of arimoclomol in SOD1 positive familial amyotrophic lateral sclerosis (ALS). Other Study ID Numbers include arimoclomol in SOD1 fALS.
Save up to 80% off your prescriptions!
How do members experience ALS Phase 2-3 Study Arimoclomol?
Top 5 reported purposes & perceived effectiveness
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Amyotrophic lateral sclerosis | 8 | 2 | |
| Participate in clinical trial | 3 | 2 |
Side effect severity
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 0 | |
| Moderate | 0 | |
| Mild | 0 | |
| None | 3 |
Learn more about our community’s experience with ALS Phase 2-3 Study Arimoclomol
What are people saying about ALS Phase 2-3 Study Arimoclomol?
18
18
members have reported taking ALS Phase 2-3 Study Arimoclomol
Join the conversation and connect with people who have taken ALS Phase 2-3 Study Arimoclomol
Last updated: